Navigation Links
Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
Date:4/28/2011

SAN DIEGO, April 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID™ Phase 3 trials will be presented at the following medical meetings:Digestive Disease Week (DDW), McCormick Place, Chicago, ILMay 7-10, 2011Poster Presentation Information:Title:

Risk of Recurrence and Time to Recurrence Following Treatment of Clostridium difficile Infection: Patient Characteristics and the Differential Effect of Fidaxomicin vs. VancomycinPresenter:

Kathleen M. Mullane, D.O.Date:

Saturday, May 7, 2011 Time:

12:00 p.m. to 2:00 p.m. Central TimeLocation:

Poster Session Hall A (MCP)Session:

Intestinal Disorders: Prebiotics, Probiotics and PathogensProgram #:

Sa1981Poster Presentation Information:Title:

High Fecal and Low Plasma Levels of Fidaxomicin and Metabolite OP-1118 inPatients with C. difficile infection:  Combined Results of Two Phase 3 TrialsPresenter:

Pamela S. Sears, Ph.D. Date:

Monday, May 9, 2011 Time:

12:00 p.m. to 2:00 p.m. Central TimeLocation:

Poster Session Hall A (MCP)Session:

Randomized Controlled Clinical TrialsProgram #:

Mo1160European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy, Milano Convention Center, Milan, ItalyMay 7-10, 2011 Oral Presentation Information:Title:

Immunosuppression and the Risk of Death, Cure Rates and Disease RecurrenceAmong Patients with Clostridium difficile InfectionPresenter:

Yoav Golan, M.D., M.S.Date:

Tuesday, May 10, 2011 Time:

10:36 a.m. to 10:48 a.m. Central European TimeLocation:

Lecture Hall Brown 1Oral Session:

C. difficile NewsPresentation #:

O504Poster Presentation Information:Title:

Cl
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 Ryan Carfley , Managing ... to sit down with Bryan Hamilton, the publisher of the ... discuss talent in the Research Triangle region of North Carolina. ... highlighted at the roundtable include the role of social ... of work/life balance and the unique role that Millennials play ...
(Date:10/27/2014)... -- The Italian company Roadrunnerfoot has ... its artificial "lower limb", after the German giant ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) , ... judgement has arrived: Roadrunnerfoot, the small Italian company ... prostheses with composite materials, has won against global ...
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information says ... Ebola concern in the United States ... The healthcare market researcher said the FDA,s Emergency Use Authorization ... diagnostic tests for the detection of the Ebola virus ... useful.  Kalorama routinely assess the IVD industry and its ...
(Date:10/27/2014)... MA (PRWEB) October 27, 2014 ... profit. SoundConnect , an industry leading unified ... its partners and agents to deliver cloud-based audio ... accelerate growth opportunities. , With SoundConnect’s Q4 ... every twenty-five video and/or web conferencing licenses sold, ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3SoundConnect Unveils Q4 Partner Incentives 2
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... a biotechnology company developing peptide therapeutics for metabolic diseases, ... as Chief Executive Officer. Dr. Gottesdiener joins Rhythm from ... President and Late-Stage Therapeutic Group Leader, with responsibility for ... and previously as head of early-stage clinical development programs. ...
... -- an open-source, web-based platform for data-intensive biomedical ... a "cloud computing" resource. A team of researchers ... and molecular biology at Penn State University; Kateryna ... State; and James Taylor from Emory University, developed ...
Cached Biology Technology:Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Rhythm Names Keith M. Gottesdiener Chief Executive Officer 2Galaxy DNA-analysis software is now available 'in the cloud' 2Galaxy DNA-analysis software is now available 'in the cloud' 3
(Date:10/29/2014)... York City on September 19, 2014, leading geneticist and ... of Genome Sciences and Medicine at the University of ... of Tel Aviv University, was awarded the 2014 Lasker-Koshland ... to her honorary degree from TAU, Prof. King was ... Medicine, and for the past 18 years she has ...
(Date:10/29/2014)... Cambridge, MA and Hebei, China — BGI Tech and ... sequencing of the Jujube genome. Jujube is the most ... Jujube genome is particularly difficult to sequence due the ... is the first time that a genome in the ... been recently published in Nature Communications ...
(Date:10/28/2014)... One of the tragic realities of cancer is ... highly toxic and their effectiveness varies unpredictably from ... is poised to change this reality by rapidly ... on an individual,s cancer before chemotherapy begins. , ... headed by Assistant Professor Melissa Skala has developed ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3
... of the embryo in the uterus have found a ... vessels that sustain the embryo. Without this protein, which is ... embryo is unlikely to survive. This is the first ... estrogen spurs cell differentiation and blood-vessel growth in the uterus ...
... techniques are increasing hope of restoring fertility for women ... destruction of reproductive tissue. The same techniques can also ... protect against extinction of endangered animal species by maintaining ... can used to produce offspring at some point in ...
... percent of fish species in North American streams, rivers ... most detailed evaluation of the conservation status of freshwater ... 700 fishes now listed represent a staggering 92 percent ... previous 1989 study published by the American Fisheries Society. ...
Cached Biology News:Gap junction protein vital to successful pregnancy, researchers find 2Cryopreservation techniques bring hopes for women cancer victims and endangered species 2Silent streams? Escalating endangerment for North American freshwater fish 2Silent streams? Escalating endangerment for North American freshwater fish 3